OBJECTIVE: The role of a-melanocyte stimulating hormone (MSH) in obesity has been well-documented. However, circulating a-MSH concentrations in obese men and their relationship with clinical indicators of obesity and glucose metabolism have not as yet been evaluated. METHODS: We measured the plasma concentrations of a-MSH in 15 obese and 15 non-obese male subjects. The relationship of the plasma concentrations of a-MSH with body mass index (BMI), body fat mass (measured by bioelectric impedance), body fat distribution (measured by computed tomography), insulin levels, insulin resistance (assessed by the glucose infusion rate (GIR) during an euglycemic hyperinsulinemic clamp study) and with the serum concentrations of leptin and TNF-a were also evaluated. RESULTS: In obese men, the plasma a-MSH concentrations were signi®cantly increased compared with those in nonobese men (P`0.02). The plasma levels of a-MSH were positively correlated with BMI (r 0.560, P`0.05), fasting insulin levels (r 0.528, P`0.05) and with visceral fat area (r 0.716, P`0.01), but negatively correlated with GIR (r 70.625, P`0.02) in obese male subjects. There were signi®cant correlations between plasma concentrations of a-MSH and visceral fat area (r 0.631, P`0.02), and GIR (r 70.549, P`0.05) in non-obese male subjects. Circulating concentrations of a-MSH were not signi®cantly correlated with the serum concentrations of leptin and TNF-a in both obese and non-obese men. CONCLUSION: Circulating concentrations of a-MSH are signi®cantly increased and correlated with insulin resistance in obese men.
Introduction
Several studies have recently demonstrated that leptin acts on the central nervous system through an amelanocyte stimulating hormone (MSH)-mediated mechanism. It is suggested that leptin activates the information transfer system of melanocortin-4 receptor in the hypothalamus, thus inhibiting feeding and increasing energy expenditure. 1 ± 3 In this connection, much attention has recently been focused on the role of a-MSH in obesity.
With regard to potential peripheral actions, a-MSH has been reported to inhibit insulin secretion from HIT-T15 cells, 4 to stimulate insulin secretion and to induce hyperglycemia in mice and in rabbits, and to inhibit the effects of cytokines including TNF-a. 5, 6 Yaswen et al reported that systemically administered a-MSH may contribute to central inhibition of feeding and peripheral inhibition of free fatty acid uptake as well as to stimulation of lipolysis in mice lacking proopiomelanocortin -derived peptide. 7 Elevated concentrations of a-MSH in HIV-infected patients have been reported, but circulating levels of a-MSH and their role in metabolic abnormalities associated with obesity have not as yet been evaluated. 8, 9 In this study, we evaluated the plasma concentrations of a-MSH and their relationship with clinical indicators of obesity in obese male subjects.
Subjects and methods

Subjects
Thirty male subjects were enrolled in the present study. The subjects were divided into two groups: 15 obese men (body mass index, BMI b 26.4 kgam 2 ) and 15 age-matched non-obese men (Table 1) . BMI was estimated by dividing the body weight (in kilograms) by the square of the height (in meters).
None of the subjects had diabetes mellitus according to the criteria of the World Health Organization (WHO), using the 75 g oral glucose tolerance test (OGTT; Trelan G 75, Shimizu, Shizuoka, Japan). 10 Five out of the 15 subjects of the obese group had impaired glucose tolerance (IGT) and all subjects of the non-obese group had normal glucose tolerance.
None of the subjects were receiving any medication that can affect insulin level or insulin sensitivity. The subjects were not engaged in any regular exercise or active dietary treatment before this study.
Informed consent was obtained from all subjects before the beginning of the study.
Study protocol and methods
Blood samples, body fat mass, body fat distribution, insulin sensitivity and arterial blood pressure were evaluated in all subjects.
Venous blood was drawn at 8 am before breakfast after one night's bed rest. After centrifugation, plasma and serum fractions were frozen at 770 C until assay. Circulating levels of a-MSH were measured by a commercial radioimmunoassay (RIA) kit (Eurodiagnostica, Malmo, Sweden). The minimum detectable concentration of a-MSH was 3 pmolal and the intra-and inter-assay coef®cients of variation of the assay were 11.8 and 13.0%, respectively. The crossreactivity with other proopiomelanocortin peptides (adrenocorticotropic hormone (ACTH) 1-24, ACTH 1-39, b-MSH and g-MSH) is`0.002%. Previous tests have shown that concentrations of a-MSH in plasma properly stored at 770 C do not change even after long periods. 8 In order to evaluate the day-to-day variations we measured the peptide 14 days after and no signi®cant changes were observed (obese men, 15.7 AE 2.3?16.3 AE 2.1 pmolal; non-obese men, 9.0 AE 1.1?9.0 AE 1.1 pmolal). Serum leptin levels were determined by RIA using a human leptin RIA kit (Linco Research Inc., St Charles, MO, USA). The minimum detectable concentration was 0.5 ngaml and the intra-and inter-assay coef®cients of variation of the assay were 4.6 and 5.0%, respectively. TNF-a in serum samples was measured using a commercially available sandwich immunoassay kit (Quantikine HS Human TNF-a immunoassay kit, R&D Systems, Mineapolis, MN, USA). The minimum detectable concentration of TNF-a using this assay was less than 0.18 pgaml and the intra-and inter-assay coef®-cients of variation of the assay were 5.6 and 7.5%, respectively. Blood glucose was measured by an automated enzymatic method; serum insulin was measured by using an immunoradiometric assay kit (Insulin Riabead II kit, Dainabot, Tokyo, Japan). In addition, we also measured blood pressure in the supine position after resting for 5 min.
Body fat mass was measured by bioelectric impedance using TBF-101 (Tanita Inc., Tokyo, Japan).
Body fat distribution was evaluated by a previously described method. 11 The total cross-sectional area, the intra-abdominal visceral fat and subcutaneous fat areas were measured in all subjects by abdominal computed tomography (CT) scanning taken at the umbilical level. Any intraperitoneal region having the same density as the subcutaneous fat layer was de®ned as a visceral fat area.
The degree of insulin resistance was evaluated by the euglycemic hyperinsulinemic clamp technique using arti®cial pancreas (STG-22, Nikkiso, Tokyo, Japan) as described previously. 12 Brie¯y, at 8 am, a priming dose of insulin (Humulin R, Shionogi, Osaka, Japan) was administered during the initial 10 min in a logarithmically decreasing manner to raise serum insulin rapidly to the desired level (1200 pmolal), which was then maintained by a continuous insulin infusion at a rate of 13.44 pmolakgamin for 120 min. The mean insulin level reached a stable level from 90 to 120 min after starting the clamp study (obese group, 1225.8AE 90.0 pmolal; non-obese group, 1207.2AE 58.4 pmolal). Blood glucose was monitored continuously and maintained at the clamped desired level (5.24 mmolal) by infusing 10% glucose. The mean amount of glucose given during the last 30 min was considered as the glucose infusion rate (GIR) and it was used as the index of the peripheral insulin sensitivity.
Statistical analysis
Data are expressed as mean AE s.e.m. The difference between the means of variables measured in obese and non-obese men were calculated by the Mann ± Whitney U-test. Correlations were analyzed by using the Spearman's rank correlation using the StatView IV software program for the Macintosh (Abacus Concepts, Berkeley, CA, USA). P`0.05 was considered as statistically signi®cant. Plasma levels of a a-MSH in obese men A Katsuki et al
Results
The plasma concentrations of a-MSH were signi®-cantly higher in obese men than in non-obese men (P`0.02; Figure 1 ). The plasma concentrations of a-MSH were signi®-cantly and positively correlated with BMI (r 0.560, P`0.05; Figure 2 ) and fasting insulin concentrations (r 0.528, P`0.05) in obese, but not in non-obese, men.
There were sigini®cant positive correlations between plasma levels of a-MSH and visceral fat areas in both obese (r 0.716, P`0.01) and nonobese (r 0.631, P`0.02) men (Figure 3) . Signi®-cant negative correlations were observed between the plasma concentrations of a-MSH and GIR in obese (r 70.625, P`0.02) and non-obese (r 70.549, P`0.05) men (Figure 4) . The plasma concentrations of a-MSH were not signi®cantly correlated with the serum concentrations of leptin and TNF-a in both obese and non-obese men.
Discussion
The present study showed that the plasma concentrations of a-MSH are signi®cantly increased in obese men compared to those in non-obese men and that they are signi®cantly correlated with fasting insulin levels, visceral fat area and insulin resistance. Figure 1 The plasma concentrations of a-MSH in obese and non-obese men. Plasma concentrations of a-MSH in obese men were signi®cantly increased compared to those in non-obese men (P`0.02). Figure 2 Correlations between the plasma concentrations of a-MSH and the BMI in obese and non-obese men. In obese men a signi®cant positive correlation was observed (r 0.560, P`0.05). Figure 3 Correlations between the plasma levels of a-MSH and the visceral fat area in obese and non-obese men. Signi®cant positive correlations were observed in obese (r 0.716, P`0.01) and non-obese men (r 0.631, P`0.02).
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It is important to clarify the mechanism of a-MSH elevation in obese men as well as its cellular source. We measured the plasma concentrations of ACTH and cortisol in obese (ACTH, 18.9AE 1.1 pgaml; cortisol, 12.5 AE 0.7 mgadl) and non-obese men (ACTH, 19.1 AE 0.6 pgaml; cortisol, 13.4 AE 1.2 mgadl) and found that there are no signi®cant differences in the levels of the factor between these two groups of subjects. a-MSH and ACTH have the same precurser and our results suggest that plasma concentrations of a-MSH do not re¯ect central nervous system levels.
A positive correlation was observed between the plasma concentrations of a-MSH and visceral fat areas in obese male subjects. Recent studies have shown that there is increased intraperitoneal adipose tissue expression of various biologically active substances such as cytokine complements. 13, 14 Visceral fat may also be a potential source of a-MSH. This relationship was also observed in non-obese men. Our non-obese male subjects included metabolically obese subjects who had accumulated visceral fat despite having normal BMI; 15, 16 this may explain the signi®-cant relationship observed in non-obese men. Further studies must be carried out to clarify the mechanism by which circulating concentrations of a-MSH are increased in obese male subjects.
An objective of this investigation was to determine whether a-MSH correlates with metabolic indicators of obesity. There was a signi®cant negative correlation between the plasma levels of a-MSH and GIR in obese men. Recently, a melanocortin receptor subtype was detected in 3T3-L1 cell lines. 17 In humans, whether binding of a-MSH to its receptor on adipose cells inhibits insulin action is unknown, but if that is the case it could explain the results of our present study. Similar correlations were also observed in nonobese men. Visceral fat may secrete a-MSH and induce insulin resistance.
Correlation between leptin and a-MSH was reported in the central nervous system, 1 ± 3 but they were not correlated in peripheral blood. Because the circulating levels of leptin vary according to gender, 1, 18 we examined the plasma a-MSH concentrations in 10 obese (age 40.0AE 2.8; BMI, 29.1 AE 1.2) and 10 non-obese (age 39.2 AE 2.6; BMI, 22.2 AE 0.6) women. Plasma levels of a-MSH in obese women (16.7 AE 2.1 pmolal) were signi®cantly elevated compared with those in 10 non-obese women (a-MSH 9.0 AE 1.1 pmolal, P`0.01), but no gender differences were found.
It was previously reported that a-MSH inhibits the biological effect of cytokines; 6,19 ± 21 however, our data did not demonstrate a signi®cant correlation between circulating levels of a-MSH and TNF-a. Serum levels of TNF-a are considered to derive from adipose tissues. 22 This observation is not in accord with the results of a previous study describing that a-MSH inhibits the effects of TNF-a secreted by monocytes at sites of in¯ammation.
Conclusion
In brief, this study showed that the plasma levels of a-MSH are signi®cantly increased and correlated with insulin resistence in obese men.
